Actionable mutational profiling in solid tumors using hybrid-capture-based next-generation sequencing in a real-world setting in Spain.

"data s1."

"CONFLICT OF INTEREST STATEMENT Jaime Rubio declares to have received personal funds for consultation and advisor role by Roche, AstraZeneca, MSD Oncology, and BMS. Manuel Domine declares to have received personal funds for consultation and advisor role by Roche, AstraZeneca, MSD Oncology, BMS, Lilly, Pfizer and Abbvie; and received travel funds by AstraZeneca, Pfizer, and BMS. Federico Rojo declares to have received personal funds for advisor role by Roche, AstraZeneca, Daiichi Sankyo, MSD, BMS, Pfizer, GSK, Novartis, Amgen, Merck, and Sophia Genetics; and received travel funds by Roche and BMS. Sandra Zazo, Sandra Pérez, Nerea Carvajal, Jenifer Plaza‐Sánchez, Rebeca Manso, Nuria Pérez‐González, Carolina Dominguez, Iván Prieto‐Potin, and Rafael Carias have no conflicts of interest to declare. David Carcedo is an employee of Hygeia Consulting which received funding from Roche to conduct the analysis. Virginia Lozano and Patricia Mohedano are employees of Roche."

"FUNDING INFORMATION This study was funded by Roche Farma S.A. Roche Farma S.A played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript. This research was also partially funded by the Spanish Ministry of Economy and Competitiveness (MINECO, AES program), grant number PI21/00142, and Fundación Jiménez Díaz Biobank PT20/00141."